Zobrazeno 1 - 10
of 159
pro vyhledávání: '"L, Pasternak"'
Shortlisted for the UK Literacy Association's Academic Book Award 2021The Bloomsbury Handbook of Reading Perspectives and Practices focuses on the experiences of reading from a young age to maturity and the different ways reading is encountered: in o
Autor:
Amy L. Pasternak, Kristen Ward, Madison Irwin, Carl Okerberg, David Hayes, Lars Fritsche, Sebastian Zoellner, Jessica Virzi, Hae Mi Choe, Vicki Ellingrod
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 2, Pp 292-304 (2023)
Abstract Understanding patterns of drug‐gene interactions (DGIs) is important for advancing the clinical implementation of pharmacogenetics (PGx) into routine practice. Prior studies have estimated the prevalence of DGIs, but few have confirmed DGI
Externí odkaz:
https://doaj.org/article/80c18bf9d06d465e9f58005f3af4afd6
Winner of the ELATE Richard A. Meade Award 2018 Identifying key areas of teacher education that cross countries and disciplines, this book provides the first extensive research-based insight into how secondary English teachers are prepared at institu
Autor:
Ramzi G. Salloum, Jeffrey R. Bishop, Amanda L. Elchynski, D. Max Smith, Elizabeth Rowe, Kathryn V. Blake, Nita A. Limdi, Christina L. Aquilante, Jill Bates, Amber L. Beitelshees, Amber Cipriani, Benjamin Q. Duong, Philip E. Empey, Christine M. Formea, J. Kevin Hicks, Pawel Mroz, David Oslin, Amy L. Pasternak, Natasha Petry, Laura B. Ramsey, Allyson Schlichte, Sandra M. Swain, Kristen M. Ward, Kristin Wiisanen, Todd C. Skaar, Sara L. Van Driest, Larisa H. Cavallari, Sony Tuteja
Publikováno v:
Implementation Science Communications, Vol 3, Iss 1, Pp 1-9 (2022)
Abstract Background Despite the increased demand for pharmacogenetic (PGx) testing to guide antidepressant use, little is known about how to implement testing in clinical practice. Best–worst scaling (BWS) is a stated preferences technique for dete
Externí odkaz:
https://doaj.org/article/622e160da30149b7bb83516b31e629d0
Autor:
Sony Tuteja, Ramzi G. Salloum, Amanda L. Elchynski, D. Max Smith, Elizabeth Rowe, Kathryn V. Blake, Nita A. Limdi, Christina L. Aquilante, Jill Bates, Amber L. Beitelshees, Amber Cipriani, Benjamin Q. Duong, Philip E. Empey, Christine M. Formea, J. Kevin Hicks, Pawel Mroz, David Oslin, Amy L. Pasternak, Natasha Petry, Laura B. Ramsey, Allyson Schlichte, Sandra M. Swain, Kristen M. Ward, Kristin Wiisanen, Todd C. Skaar, Sara L. Van Driest, Larisa H. Cavallari, Jeffrey R. Bishop, for the IGNITE Pharmacogenetics Working Group
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 2, Pp 371-383 (2022)
Abstract There is growing interest in utilizing pharmacogenetic (PGx) testing to guide antidepressant use, but there is lack of clarity on how to implement testing into clinical practice. We administered two surveys at 17 sites that had implemented o
Externí odkaz:
https://doaj.org/article/8db7d4a68b104a13ba4ac33d91a1855f
Publikováno v:
Therapeutic Drug Monitoring. 45:95-101
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0f7108b8c91a872be4fa5cfcf275e4a1
https://doi.org/10.1097/ftd.0000000000001002
https://doi.org/10.1097/ftd.0000000000001002
Publikováno v:
JCO Oncol Pract
PURPOSE: Patients who carry reduced-activity DPYD polymorphisms have increased fluoropyrimidine (FP) toxicity risk. Although pretreatment DPYD testing is recommended throughout most of Europe, it is not recommended in the United States, and adoption
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f6ac6cfc34adb7742b456e7c09d474e5
https://pubmed.ncbi.nlm.nih.gov/35239419
https://pubmed.ncbi.nlm.nih.gov/35239419
Autor:
Amy L. Pasternak, Robinson Seda, Joseph Lipa, Rachel L. McDevitt, Oxana V. Crysler, Paul L. Swiecicki, Bryan J. Schneider, Brett Vanderwerff, N. Lynn Henry, John C. Krauss, Vaibhav Sahai, Daniel L. Hertz
Publikováno v:
Clinical Pharmacology & Therapeutics.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::294787d8f3f41099c66054cc5de4a589
https://doi.org/10.1002/cpt.2936
https://doi.org/10.1002/cpt.2936
Publikováno v:
JCO Oncology Practice. 18:e958-e965
PURPOSE: Patients who carry reduced-activity DPYD polymorphisms have increased fluoropyrimidine (FP) toxicity risk. Although pretreatment DPYD testing is recommended throughout most of Europe, it is not recommended in the United States, and adoption
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b48657f80b23712d11ef2117b46d3ba
https://doi.org/10.1200/op.21.00874
https://doi.org/10.1200/op.21.00874
Publikováno v:
Pharmacogenet Genomics
OBJECTIVES: Evaluations from pharmacogenetics implementation programs at major U.S. medical centers have reported variability in the clinical adoption of pharmacogenetics across therapeutic areas. A potential cause for this variability may involve th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1d1932266ad22c7f4fe136de63e51f0
https://pubmed.ncbi.nlm.nih.gov/34412102
https://pubmed.ncbi.nlm.nih.gov/34412102